[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"environmental-exposures\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:environmental-exposures":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,53,79],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":37,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":5},"100639368","phase-2-use-of-bile-acid-binding-resins-to-decrease-pfas-levels-via-colesevalem-in-veterans-study-100639368",false,"NCT07592858","Use of Bile Acid Binding Resins to Decrease PFAS Levels Via Colesevalem in Veterans Study","Use of Bile Acid Binding Resins to Decrease Systemic Per- and Polyfluoroalkyl Substance (PFAS) Levels and Improve Serum Lipid Profiles in Veterans: PFAS Reduction in Veterans Via Colesevalem Study (PAVERS) Study","PAVERS","Inclusion:\n\n* Male or female Veterans aged 25- 65 who have serum PFAS \\>20 ng\u002Fml exceeding National Academy of Science guidance.\n* Written informed consent will be obtained.\n* Outpatient.\n* Agreeable to participate in sharable data and biorepository.\n\nExclusion:\n\n* Under the age of 25 years\n* Unable or unwilling to sign the informed consent statement and HIPAA Authorization form\n* Females who are pregnant (confirmed by urine pregnancy test), nursing or planned pregnancy within study period.\n* Patients with hypertriglyceridemia, vitamin deficient patients, hyperthyroidism and diabetic, pancreatitis and intestinal and bowel obstruction\n* Be receiving any investigational drug other than Colesevelam or participating in any other investigational study.\n* Significant medical illnesses that may limit the subject's ability to complete follow-up visits, in the opinion of the investigator.\n* Be receiving any non-standard immunosuppression protocol or other non-standard treatment that could affect interpretation of the study results.\n* Those with significant cardiovascular disease including treatment with inotropes.\n* Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.\n* Active substance abuse if this, in the opinion of the investigator, will interfere with the subject's ability to adhere to the study protocol.",true,"ALL","25 Years","65 Years",{"count":22,"type":23},50,"ESTIMATED","INTERVENTIONAL",[26],"PHASE2","The goal of this study is to test the efficacy and feasibility of Colesevelam administration (50% of the recommended dose) to reduce serum PFAS concentration in the Veteran population who have serum PFAS levels that exceed the National Academies Science criteria (PFASsix \\> 20 ng\u002Fml) using a double blind-placebo controlled study. Based on PFAS prevalence in serum samples, we anticipate recruiting up to n=500 Veterans to meet the goal of n=50 study participants to receive intervention or placebo. The primary outcome will be initial and final PFAS content in serum (total and 7 individual PFAS). The secondary outcome will be initial and final serum biomarkers related to lipid metabolism. As an exploratory aspect to the proposal, we will also measure fecal PFAS, bile acids, and microbial diversity to examine associations between PFAS content and bile acid levels and microbiome. Fecal PFAS, bile acid content, and microbiome may also be measured.",[29,30,31,32,33,34,35,36],"PFAS","Environmental Exposures","Occupational Exposure to Chemicals","Military Exposure","Burn Pit Exposure","Forever Chemicals","Hyperlipidemias, Hypercholesterolemia, Mixed Dyslipidemia","Hyperlipidemia (E.G., Hypercholesterolemia)",[29,38,39,40],"Military exposure","Forever chemicals","Colesevelam","NOT_YET_RECRUITING","2026-05-11",{"date":44,"type":45},"2026-05-18","ACTUAL",{"date":47,"type":23},"2026-07-01",{"date":49,"type":23},"2029-09-29",{"name":51,"class":52},"University of Rhode Island","OTHER",{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":17,"sex":18,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":4,"studyType":24,"phases":64,"briefSummary":66,"conditions":67,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":5},"100593342","effects-of-lpg-and-ventilation-interventions-on-reducing-hap-and-improving-cardiopulmonary-health-100593342","NCT07005193","Effects of LPG and Ventilation Interventions on Reducing HAP and Improving Cardiopulmonary Health","Effects of Liquefied Petroleum Gas and Ventilation Interventions on Reducing Household Air Pollution From Solid Fuel Use and Improving Cardiopulmonary Health: A Multi-center, 2×2 Factorial Randomized Controlled Trial","1. Inclusion Criteria Primary Participants：\n\n   * Aged 18-75 years;\n   * Local permanent residents with no plans for long-term travel or relocation within one year;\n   * Kitchen suitable for installation of ventilation facilities;\n   * Responsible for daily household cooking, cooking ≥5 times per week;\n   * To control for community penetration of pollution, households will be preferentially recruited in naturally ventilated, open villages, avoiding valleys or basins that hinder pollutant dispersion; preference for detached houses with ≥10 m distance from neighboring kitchens and well-sealed doors and windows.\n\n   Secondary Participants:\n   * Elderly individuals aged 65-75 living with the primary participant;\n   * Children aged 3-6 living in the same household.\n2. Exclusion Criteria:\n\n   * Clinical diagnosis of major chronic diseases such as severe respiratory diseases, cardiovascular diseases, malignant tumors, or end-stage renal disease;\n   * Pregnant or breastfeeding women;\n   * Current smokers or individuals with self-reported exposure to productive dust or other occupational hazards;\n   * Individuals who are unable to fully understand the study process or clearly express their own complaints, such as those with psychiatric disorders or severe neuroses, or who cannot cooperate with the study for other reasons.","18 Years","75 Years",{"count":63,"type":23},1200,[65],"NA","The goal of this clinical trial is to evaluate the independent and synergistic effects of liquefied petroleum gas (LPG) substitution and improved ventilation on household air pollution (HAP) reduction and cardiopulmonary health. The main questions it aims to answer are:\n\n1. Does LPG substitution or improved ventilation reduce HAP and improve cardiopulmonary health?\n2. Would the combined intervention of LPG substitution and improved ventilation outperform single interventions?\n3. What is the cost-effectiveness of such interventions, and are they sustainable?\n4. Does the intervention reduce the incidence of cardiopulmonary clinical events?\n\nParticipants will be randomized in 4 groups:\n\nA: Solid fuel + no ventilation facilities group (300 households): Continued use of solid fuels without installation of ventilation facilities and receipt of standardized health education. No LPG stoves or ventilation equipment will be provided during the intervention period. However, after the primary endpoint assessment at 12 months, all households in Group A will be provided with LPG stoves and ventilation facilities of equivalent specifications free of charge, along with health guidance. Phased cash compensation will be provided during the intervention period.\n\nB: Liquefied petroleum gas (LPG) + no ventilation facilities group (300 households): Provided with LPG stoves and instructed to use them during cooking, with regular LPG supply throughout the intervention period. Participants will also receive standardized health education.\n\nC: Solid fuel + ventilation facilities group (300 households): Continued use of solid fuels while being provided with ventilation facilities and instructed to use them during cooking. Electricity costs will be compensated during the intervention period. Participants will also receive standardized health education.\n\nD: LPG + ventilation facilities group (300 households): Provided with both LPG stoves and ventilation facilities and instructed to use both during cooking. Regular LPG supply and electricity cost compensation will be provided throughout the intervention period. Participants will also receive standardized health education.",[68,30],"Cardiopulmonary Function","RECRUITING","2026-03-15",{"date":72,"type":45},"2026-03-17",{"date":74,"type":45},"2025-07-01",{"date":76,"type":23},"2029-06-30",{"name":78,"class":52},"Huazhong University of Science and Technology",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":17,"sex":87,"minAge":60,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":90,"phases":4,"briefSummary":91,"conditions":92,"keywords":105,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":132},"100607934","early-life-malnutrition-environmental-enteric-dysfunction-and-microbiome-trajectories-100607934","NCT07195006","Early Life Malnutrition, Environmental Enteric Dysfunction and Microbiome Trajectories","Early Life Diarrhoea Episode(s), Malnutrition, Environmental Enteric Dysfunction and Microbiome Trajectories From Birth Until 3 Years of Life ; The University of Zimbabwe Birth Cohort Study-2 (UZBCS-2)","UZBCS-2","Inclusion Criteria for Cases:\n\n* MUAC ≤23 cm in pregnancy\n* ≥18 years' old\n* At least 20 weeks' gestational age\n* Height ≥150 cm\n* Planning to be staying in the study area for the next 3 years\n* Willing to participate and comply with all study requirements and procedures.\n\nAny pregnant woman meeting the above eligible criteria regardless of HIV status who meet the above inclusion criteria will be invited to participate in the study\n\nInclusion criteria for Controls\n\n* Age, HIV status, gestational age at enrolment, and area residence matched normo-nourished peers with MUAC ≥25 - ≤35 cm\n* Haemoglobin level of ≥11g\u002FdL\n* ≥18 years' old\n* At least 20 weeks' gestational age\n* Height ≥150 cm\n* Planning to stay in the study area for the next 3 years\n\nExclusion Criteria\n\n* Acute or chronic conditions in mothers interfering with the study according to the judgment of the investigator (HIV infection is not an exclusion criterion)\n* Presence of severe mental health disorders interfering with study procedures according to the judgment of the investigator.","FEMALE",{"count":89,"type":23},368,"OBSERVATIONAL","Malnutrition in women of reproductive age remains a public health concern in Sub-Saharan Africa (SSA). Malnutrition during pregnancy affects foetal growth with a tendency of the exposed infants to also develop it. The interaction of the mother with the infant shapes the seeding and the trajectory of the infant intestinal microbiota which is crucial for development of a healthy immune system Malnutrition has been associated with intestinal inflammation, intestinal leakage and reduced calorie absorption. Early life malnutrition and environmental enteric dysfunction (EED) immunopathology remains poorly described in the context of mother-infant dyads. This is essential as malnutrition, poor water, sanitation and hygiene (WASH), including the presence of infectious diseases limit the developmental potential of the exposed infants in SSA, including Zimbabwe. In addition, maternal stress and poor mental health may also affect standard hygiene practices, including how a mother cares for her baby, potentially aggravating EED and the risk of the infant being malnourished.\n\nPrimary outcomes\n\n1. Infant malnutrition and recovery.\n2. Gut dysfunction (gut inflammation, leaky gut, malabsorption, dysbiosis)\n3. Diarrhea episodes, defined as any episode of acute diarrhoea (≥3 passages of loose stool within 24 hours as reported by the mother) occurring before the next study visit.\n\nDefinition of malnutrition outcomes to be assessed in babies born to malnourished women, is a mid- upper arm circumference (MUAC) \\\u003C23cm;\n\n* MUAC for age: Malnourished defined as those below -2 standard (SD) of the World Health Organisation (WHO) reference\n* Weight-for-age: Underweight defined as those below -2SD WHO reference\n* Weight-for-height: Wasted defined as those below -2SD WHO reference\n* Height-for-age: Stunted defined as those below -2SD WHO reference\n* Z-scores (as they are i.e. a continuous variable, taking age of infants into account)\n* A composite variable, any of malnourished, underweight, wasted or stunted.",[93,94,95,96,97,98,99,100,101,102,103,30,104],"Malnutrition Pregnancy","Malnutrition in Children","Malnutrition (Calorie)","Environmental Enteric Dysfunction","Gut Dysbiosis","Gut Permeability, Gut Inflammation","Diarrhea Infectious","Maternal Stress","Child Mental Health","Natural Killer Cell Mediated Immunity","Mycotoxin Biomonitoring","Cell-Mediated Immune Deficiency",[106,107,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122],"diarrhoeal episodes","short chain fatty acids receptor agonists","intestinal inflammation, leakage and calory extraction","toxins in drinking water and food","macro- and micronutrient composition of breast milk","human anti-Gal antibodies","mitochondria health and nutrient uptake","endothelial dysfunction and oxidative stress","hormonal mediated molecular signalling mechanisms","interaction of epigenetics & socioeconomic factors","microbiota, pathobionts and oral microbiota","metagenomics","undernutrition and intestinal infections","infant mortality, morbidity within 1st 1000 days of life","low mid upper arm circumference","sleep adequacy in maternal mental health","chronic inflammation","2025-09-18",{"date":125,"type":45},"2025-09-26",{"date":127,"type":45},"2025-01-27",{"date":129,"type":23},"2032-12-31",{"name":131,"class":52},"University of Zimbabwe",1]